pf-06273340
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2012 (NCT01601834)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
NTRK2 inhibitor
- Nerve growth factor receptor Trk-AINHIBITOR
NTRK1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(CO)n1cc(C(=O)c2cncc(NC(=O)Cc3ccc(Cl)cn3)c2)c2cnc(N)nc21- Mol. weight
- 479.93 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4212531 ↗
Also known as
- pf-06273340
- pf-06273340
- pf-06273340
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02260947 | Phase 1 | Oct 1, 2014 | Pfizer |
| NCT01934738 | Phase 1 | Oct 1, 2013 | Pfizer |
| NCT01706796 | Phase 1 | Nov 1, 2012 | Pfizer |
| NCT01601834 | Phase 1 | May 1, 2012 | Pfizer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 4 | 4 | 1 | 2012 |
1 organizations
Page 1 / 1